Galera sells avasopasem/rucosopasem assets to Biossil for $3.5M upfront, up to $105M milestones

Galera Therapeutics, Inc.

Biossil Inc. acquires all of Galera's dismutase mimetic assets, including avasopasem (GC4419) and rucosopasem (GC4711).
Upfront payment of $3,500,000; potential regulatory/commercial milestones and contingent value rights total up to $105,000,000.
Biossil assumes rights and obligations under the 2018 Clarus IV Galera Royalty agreement (affiliated with Blackstone Life Sciences).
Purchase Agreement contains customary representations, warranties, and covenants; filing of full agreement will follow in next Form 10-Q.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.